Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access
Introduction: Access to pimavanserin, the only Parkinson disease–related psychosis treatment approved by the FDA, is restricted by insurance requirements, a limited distribution network, and high costs. Following initiation, patients require monitoring for safety and effectiveness. The primary objec...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Association of Psychiatric Pharmacists
2021-05-01
|
| Col·lecció: | Mental Health Clinician |
| Matèries: | |
| Accés en línia: | https://theijpt.org/doi/pdf/10.9740/mhc.2021.05.187 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|